USC Experts Can Discuss Newly Approved Alzheimer's Drug and Related Dementia Research
July 03, 2024
July 03, 2024
LOS ANGELES, California, July 3 (TNSres) -- The University of Southern California issued the following news release:
The US Food and Drug Administration on Tuesday approved a new drug designed to slow the progression of early symptomatic Alzheimer's disease. The drug, donanemab, was shown in studies to modestly slow cognitive decline in initial stages of the disease but it also carries safety risks. USC experts can speak about the potential impact of amyloid-clearing medications.
The US Food and Drug Administration on Tuesday approved a new drug designed to slow the progression of early symptomatic Alzheimer's disease. The drug, donanemab, was shown in studies to modestly slow cognitive decline in initial stages of the disease but it also carries safety risks. USC experts can speak about the potential impact of amyloid-clearing medications.